Truist reiterates Buy on RadNet stock after ONRAD acquisition
Truist Securities reiterated a Buy rating and $94 price target on RadNet (RDNT) after its $700M acquisition of ONRAD. The deal includes cash, shares, and an earnout. RadNet's stock trades at $73.77, with analysts citing growth potential. The company reported strong Q2 2026 results, raising guidance and prompting price target increases from multiple analysts.
How this was made
The 30-second read
Why it matters
The acquisition expands RadNet's service offering, potentially boosting revenue and margins, which supports the raised price target.
Market read
Analyst upgrade and a sizable acquisition provide a clear catalyst for RDNT, making the news highly relevant for traders.
What to watch
Potential regulatory scrutiny of the $700M deal and the earnout component could affect future earnings.
Background
RadNet is a freestanding imaging center operator that recently posted strong Q2 results and raised guidance.
Ticker impact
Truist reiterated a Buy rating and raised the price target to $94 after RadNet announced a $700M acquisition of ONRAD.
likely upward pressure as the market prices in the acquisition synergies and higher target.
The deal adds a new revenue segment and analysts have increased the price target, indicating bullish expectations.
Market effects
The radiology services sector may see increased M&A activity as larger players seek to add professional services capabilities.
U.S. healthcare services stocks could benefit from perceived consolidation trends.
Limited to U.S. healthcare and imaging markets; no broad macro impact.
Counterpoint
The acquisition could strain RadNet's balance sheet and integration risk may outweigh upside.
Key entities
- CompanyRadNet
U.S.-listed imaging services provider (NASDAQ:RDNT).
- CompanyONRAD
Provider of teleradiology and in‑hospital radiology staffing services.
